Ixabepilone is a FDA approved drug for the treatment of metastatic or locally advanced breast
cancer after failure of chemotherapy. SBRT is a treatment method to deliver a high dose of
radiation to the target, utilizing either a single dose or a small number of treatments with
a high degree of precision within the body. The combination of Ixabepilone with SBRT is not
an approved treatment at this time.
1. Biopsy proven triple negative invasive ductal or lobular metastatic breast cancer.
Tumor estrogen, progesterone, and HER2 (tested by IHC or FISH) negative disease. (ER-
defined as </=1% by IHC, PR- defined as </=1% by IHC, and HER2- by IHC 1+. If HER2
result by IHC is 2+ (equivocal), the tumor must be confirmed to be HER2- by FISH.
2. Age ≥ 18 years.
3. Patients must not have started Ixabepilone treatment more than 5 weeks prior to
initiation of SBRT treatment.
4. Patients can have up to 6 sites of active extracranial disease(</=3 in the liver = one
site and </=3 in the lung= one site) identified by CT scan, or PET/CT, within 8 weeks
prior to initiation of SBRT (up to 2 contiguous vertebral metastasis will be
considered a single site of disease). Maximum number of lesions treated is deemed as
feasible per the treating radiation oncologist; ie: A patient with 4 right axillary
lymph nodes, L1-L2 bone metastasis, 3 lung lesions, 1 left lung lesion, 2 liver
lesions, and T2-T3 bone metastasis would be defined as having 6 sites of disease.
Criteria to define a lesion in any location as a metastasis requiring local treatment
as one of the sites for SBRT is any lesion clinically felt to be viable; defined as
enlarging on CT/MRI or having persistent FDG avidity (Either SUV>3 or increase of
SUV>20% over a 6 month interval).
5. Patients with skin nodules, skin invasion, or skin ulceration are eligible, if
treatment with conventional radiation (at discretion of radiation oncologist) or
surgery is planned. SBRT to skin nodules is not advised because of risk of skin
6. . Patients must have had failure of an anthracycline, a taxane and capecitabine as per
FDA approved criteria.
7. Performance status of ECOG 0,1, or 2.
8. Adequate organ and marrow function as defined below:
- leukocytes ≥ 3,000/mcL
- absolute neutrophil count ≥ 1,500/mcL
- platelets ≥ 100,000/mcl
- total bilirubin within normal institutional limits
- AST(SGOT)/ALT(SPGT) ≤ 2.5 X institutional upper limit of normal
- creatinine within normal institutional limits
9. Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry, for
the duration of study participation, and for 90 days following completion of therapy.
Should a woman become pregnant or suspect she is pregnant while participating in this
study, she should inform her treating physician immediately.
9.1 A female of child-bearing potential is any woman (regardless of sexual
orientation, having undergone a tubal ligation, or remaining celibate by choice) who
meets the following criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
has had menses at any time in the preceding 12 consecutive months).
10. Patients who would be receiving SBRT for lung tumors who are known or must have a
documented forced expiratory volume in 1 second (FEV1)>/=30%.
11. Must have a CT C/A/P, or PET/CT scan within 8 weeks of enrollment.
12. Ability to understand and the willingness to sign a written informed consent
1. Patients may not be actively receiving any other investigational agents.
2. Patients with untreated brain metastasis (patients can have whole brain radiation or
stereotactic radiation to brain prior to enrollment).
3. Patients with leptomeningeal disease.
4. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Agent(s) used in study. Patients with a history of severe reactions to
Cremephor EL or its derivatives (polyoxyethylated castor oil) are ineligible as
Ixabepilone contraindicated in these patients
5. Because the tolerance dose of SBRT to the gastrointestinal tract is not established,
patients with metastatic disease invading the esophagus, stomach, intestines, or
mesenteric lymph nodes will not be eligible.
6. Patients with more than 6 discrete extra-cranial sites.
7. Treatment for other carcinomas within the last 5 years, except cured non-melanoma skin
and treated in-situ cancers.
8. Patients must not be pregnant or nursing due to the potential for congenital
abnormalities and the potential of this regimen to harm nursing infants.
9. Patients must not be on concomitant CYP3A4 inhibitors or inducers (see section 4.3).